University of Michigan-Ann Arbor · Biomedical EngineeringBladder Cancer CRISPR Therapeutics Lab
Mats Ljungman · Ann Arbor, Michigan
Research Focus
Dr. Mats Ljungman’s lab at the University of Michigan focuses on developing innovative cancer therapies using CRISPR technology, specifically targeting bladder cancer cells. The lab's research aims to precisely induce DNA damage in cancer cells by using a split CRISPR enzyme approach that minimizes effects on normal cells. Their goal is to advance this technique towards clinical trials, providing a new avenue for effective treatments for bladder cancer.
CRISPRbladder cancerstructural variantsgene editingprecision therapy
Research Aims
3AIM 01Map potential Fok1-dCas9 binding toxicity genome-wide.
AIM 02Deliver CRISPR reagents to bladder cells in culture.
AIM 03Assess efficacy of Precision KLIPP Therapy in a pre-clinical mouse model of bladder cancer.
Skills the Lab Values
CRISPR/Cas technologycell cultureanimal modelsDNA sequencingbioinformatics
Output against the department
Publications470top 18% of dept.106th of 595
this lab
most publishedleast published
Citations11ktop 32% of dept.192nd of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.